Generics Body Attacks WHO's 'Immature' Biological Qualifier Scheme
This article was originally published in SRA
Executive Summary
The World Health Organization's 'biological qualifier' scheme has its supporters and its detractors, with the former believing it will improve drug use and monitoring, and the latter thinking it at best superfluous and at worst a potential source of confusion and regulatory misalignment.
You may also be interested in...
WHO To Pilot ‘Biological Qualifier’ Scheme Despite Protests From Biosimilars Industry
The World Health Organization has decided to pursue its “Biological Qualifier” scheme despite concerns that it may conflict with other traceability systems. Calls by the European biosimilars industry to put the scheme on ice appear to have fallen on deaf ears.
WHO To Pilot ‘Biological Qualifier’ Scheme Despite Protests From Biosimilars Industry
The World Health Organization has decided to pursue its “Biological Qualifier” scheme despite concerns that it may conflict with other traceability systems. Calls by the European biosimilars industry to put the scheme on ice appear to have fallen on deaf ears.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.